Announcements Trials

Browse Landscape

Status

Enrolling by invitation 1

Sponsor Class

Study Type

Observational 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Stomach Neoplasms 6 Esophageal Neoplasms 4 Gastrointestinal Neoplasms 3 Pancreatic Neoplasms 2 Neoplasm Metastasis 2 Adenocarcinoma 2 Solid Tumor 1 Rectal Neoplasms 1 Pathologic Complete Response 1 Neoplasms, Unknown Primary 1 Nasopharyngeal Carcinoma 1 Locally Advanced Gastric Adenocarcinoma 1 Hand-Foot Syndrome 1 Colorectal Neoplasms 1 Colonic Neoplasms 1 Biliary Tract Neoplasms 1 Bile Duct Neoplasms 1 Adenocarcinoma Of Esophagus 1

Interventions

Fluorodeoxyglucose F18 7 Irinotecan 4 Fluorouracil 4 Cyclophosphamide 4 Bevacizumab 4 toripalimab 3 pembrolizumab 3 olaparib 3 Radiosurgery 3 Cisplatin 3 Capecitabine 3 vistusertib 2 tislelizumab 2 spartalizumab 2 fludarabine 2 atezolizumab 2 apatinib 2 Temozolomide 2 Technetium 2 Specimen Handling 2 Sirolimus 2 Radiotherapy 2 Proton Therapy 2 Paclitaxel 2 Leucovorin 2 Letrozole 2 Hydroxychloroquine 2 Everolimus 2 Drug Therapy 2 Docetaxel 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Solid Tumor × tegafur-gimeracil-oteracil × Clear all

NCT04260269 2024-12-12

CardioSwitch

Helsinki University Central Hospital

Enrolling by invitation

Other solid neoplasm

Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon ⚡